MétaCan
Menu
Back to cohort

582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

2023· article· en· W4388048048 on OpenAlexaff
Julian Olea, Homa Dadrastoussi, Eduardo Fernandez Hernandez, Hugo Lara Martinez, Kaijin Wu, Houra Loghmani, Thomas Heineman, Richard Trauger, Matt Coffey, Fernando Salvador, Joaquín Gavilá, Tomás Pascual, Luís Manso, Aleix Prat, Akil Merchant, Kevin R. Kelly

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2023
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Research and Treatments
Canadian institutionsOncolytics Biotech (Canada)
Fundersnot available
KeywordsAtezolizumabMedicineTumor microenvironmentBreast cancerImmune systemOncologyInternal medicineAntibodyTriple-negative breast cancerCancerCancer researchImmunotherapyImmunologyNivolumab

Abstract

fetched live from OpenAlex

<h3>Background</h3> Pelareorep (pela) is an intravenously delivered, non-modified oncolytic reovirus that shows anti-tumor activity through innate and adaptive immune responses as well as direct tumor lysis. Previous data from the window of opportunity AWARE-1 study demonstrated synergy between pela in combination with atezolizumab, demonstrating a favorable immunologic response in tumors from early breast cancer (eBC) patients.<sup>1</sup> To understand the complex tumor microenvironment (TME) and immune responses in patients before and after treatment, we used imaging mass cytometry (IMC) to perform single cell, highly multiplexed, analysis of their tissue samples. <h3>Methods</h3> Newly diagnosed HR+/HER2- eBC patients were enrolled into two cohorts: Cohort 1: pela + letrozole (n=10); and Cohort 2: pela + letrozole + atezolizumab (n=10). Pela was administered on days 1, 2 and 8, 9, and atezolizumab was given on day 3. Tumor biopsies (FFPE samples) collected pre-treatment (D1) and on days 3 (D3, prior to atezolizumab administration) and approximately on day 21 (when tumors were surgically removed) were examined by IMC. A marker panel of 37 antibodies conjugated to a unique metal isotope was assembled. Pixel-based classification was performed in Ilastik to generate cell probability masks and processed in Cellprofiler. RStudio was used to phenotype the data with PhenoGraph. Expression and neighborhood analysis was generated in RStudio. <h3>Results</h3> Preliminary analysis with IMC reveals significant enrichment of cytotoxic T cells between D3 and surgery and between D1 and surgery. The Ki67+ subset of tumor shows a significant decrease in abundance between D1 and D3, D3 and surgery, and D1 and surgery. The general tumor subset shows a significant decrease in abundance between the D3 and surgery timepoints. Expression of PD-L1 significantly increases between the screening and D3 timepoints and significantly decreases between the D3 and surgery timepoints, conceivably explained by the immune-mediated destruction of tumor cells. Nearest neighbor distance analysis shows that cytotoxic T cells are significantly closer to tumor when comparing the screening and surgery timepoints. <h3>Conclusions</h3> In accordance with the prior AWARE-1 results, IMC demonstrated an enhanced immune state of the tumors after treatment. IMC allows us to analyze the potent immune response and cellular interactions in the TME and characterization of these complex interactions provides a better understanding of the key mechanisms of action of these treatments in order to plan future clinical trials. <h3>References</h3> Loghmani <i>et al</i>. SABCS 2022

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.586
Threshold uncertainty score0.860

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.260
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicCancer Research and TreatmentsFrench-language works237,207